Reviews preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-α in cynomolgus macaques

Journal of Immunotoxicology

Volumn 1, Issue 3-4, 2005, Pages 131-139

  Martin, Pauline L ^a   Cornacoff, Joel ^a   Prabhakar, Uma ^a   Lohr, Thomas ^a   Treacy, George ^a   Sutherland, Jessica E ^b   Hersey, Sarah ^b   Martin, Elise ^b  

^a CENTOCOR INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Monoclonal antibody

Indexed keywords

EID: 29044445019     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.1080/15476910490894904     Document Type: Review

References (24)

1. Akira, S., Hirano, T., Taga, T., and Kishimoto, T. 1990. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 4:2860-2867.
2. Choy, E. H., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., Yoshizaki, K., Nishimoto, N., Kishimoto, T., and Panayi, G. S., 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double blind, placebo-controlled, doseescalation trial. Arthritis Rheum. 46:3143-3150.
3. Ito, H., Hirotani, T., Yamamoto, M., Ogawa, H., and Kishimoto, T. 2002. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J. Gastroenterol. 37:56-61.
4. Kawano, Y., Noma, T., Kou, K., Yoshizawa, I., and Yata, J. 1995. Regulation of human IgG subclass production by cytokines: human IgG subclass production enhanced differentially by interleukin-6. Immunology 84:278-284.
5. Kopf, M., Herren, S., Wiles, M. V., Pepys, M. B., and Kosco-Vilbois, M. H. 1998. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J. Exp. Med. 188:1895-1906.
6. May, L. T., Neta, R., Moldawer, L. L., Kenney, J. S., Patel, K., and Sehgal, P. B. 1993. Antibodies chaperone circulating IL-6. J. Immunol. 151:3225-3236.
7. May, L. T., Viguet, H., Kenney, J. S., Ida, N., Allison, A. C., and Sehgal, P. B. 1992. High levels of "complexed" interleukin-6 in human blood. J. Biol. Chem. 267:19698-19704
8. Mihara, M., Kotoh, M., Nishimoto, N., Oda, Y., Kumagai, E., Takagi, N., Tsunemi, K., Ohsugi, Y., Kishimoto, T., Yoshizaki, K., and Takeda, Y. 2001. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol. 98:319-326.
9. Mihara, M., Nishimoto, N., Yoshizaki, K., and Suzuki, T. 2002. Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. Immunol. Lett. 84:223-229.
10. Ndubuisi, M. I., Patel, K., Rayanade, R. J., Mittelman, A., May, L. T., and Sehgal, P. B. 1998. Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J. Immunol. 160:494-501.
11. Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Ta keuchi, T., Hashimoto, J., Azuma, J., and Kishimoto, T. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 50:1761-1769.
12. Okazaki, M., Yamada, Y., Nishimoto, N., Yoshizaki, K., and Mihara, M. 2002. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol. Lett. 84:231-240.
13. Paleolog, E. 2003. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin. Investig. Drugs 12:1087-1095.
14. Paleolog, E. M., Hunt, M., Elliot, M. J., Feldman, M., Maini, R. N., and Woody, J. N. 1996. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibodyinrheunmatoid arthritis. Arth. Rheum. 39:1082-1091.
15. Pasarakis, M., Alexopoulou, L., Episkopou, V., and Kollia, G. 1996. Immune and inflammatory responses in TNFα-deficient mice: a critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, in the maturation of the humoral immune response. J. Exp. Med. 184:1397-1411.
16. Shealy, D. J., Wooley, P. H., Emmell, E., Volk, A., Rosenberg, A., Treacy, G., Wagner, C. L., Mayton, L., Griswold, D. E., and Song, X. Y. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 2002;4:R7.
17. Smith, P. C., Keller, E. T. 2001. Anti-interleukin-6 monolcolanal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48:47-53.
18. Tak, P. P., Taylor, P. C., Breedveld, F. C., Smeets, T. J. M., Daha, M. R., Kluin, P. M., Meinders, A. E., and Maini, R. N. 1996. Decreases in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arth. Rheum. 39:1077-1081.
19. Takagi, N., Mihara, M., Moriya, Y., Nishimoto, N., Yoshizaki, K., Kishimmoto, T., Takeda, Y., and Ohsugi, Y. 1998. Interleukin-6 receptor blockage ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41:2117-2121.
20. Thornhill, M. H., Wellicome, S. M., Mahiouz, D. L., Lanchbury, J. S., Kyan-Aung, U., and Haskard, D. O. 1991. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T-cells. The contribution of vascular cell adhesion molecule-1-dependent and independent binding mechanisms. J. Immunol. 146:592-598.
21. Trikha, M., Corringham, R., Klein, B., and Rossi, J.-F. 2003. Targeted antiinterleukin-6 monoclonal antibody therapy forcancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9:4653-4665.
22. Tsunenari, T., Akamatsu, K., Kaiho, S., Sato, K., Tsuchiya, M., Koishihara, Y., Kishimoto, T., and Ohsugi, Y. 1996. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Anticancer Res. 16:2537-2544.
23. Van Zaanen, H. C. T., Lokhorst, H. M., Aarden, L. A., Rensink, H. J. A. M., Warnaar, S. O., van der Lelie, J., and van der Oers, M. H. J. 1998. Chimeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalation study. Br. J. Haematol. 102:783-790.
24. Victoratos, P., Yiangou, M., Avramidis, N., and Hadjipetrou, L. 1997. Regulation of cytokine gene expression by adjuvants in vivo. Clin. Exp. Immunol. 109:569-578.